Novalis Biotech Incubation, a Belgian venture capital investment fund, is investing seed capital in Cergentis for an undisclosed amount.
Cergentis, an innovative leader in genomics, provides kits and services based on its proprietary Targeted Locus Amplification (TLA) technology to leading diagnostic labs, research institutes and pharmaceutical companies worldwide. TLA enables rapid, cost-effective and complete next generation sequencing of genes of interest as well as the detection of all single nucleotide and structural variants. Cergentis recently launched TLA for complete cancer gene sequencing, reporting superior data over conventional diagnostic and gene sequencing techniques in FFPE tumour samples.
Wim Van Criekinge, co-founder of Novalis, and board member of Cergentis added:
"We are pleased to invest in Cergentis. Their proprietary Target Locus Amplification (TLA) technology is unique and allows the most advanced genome characterization to date”.
Jan Dekker, CEO of Cergentis:
"We are delighted that Novalis has decided to invest in Cergentis. We appreciate their trust in our company and their support in our mission to improve the quality of genetic research and human healthcare worldwide.”
About Novalis Biotech Incubation: Novalis seeds biotechnology and life sciences related companies. Their core competence lies in the interaction between bioinformatics, genomics and digitalization in life sciences.